| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4
|
Tod, Michel
|
|
2018
|
|
4 |
p. 503-523
|
artikel
|
| 2 |
A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics
|
Philippe, Michaël
|
|
2016
|
|
4 |
p. 435-447
|
artikel
|
| 3 |
Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?
|
Kumta, Nilesh
|
|
2017
|
|
4 |
p. 439-454
|
artikel
|
| 4 |
Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses
|
El Hassani, Mehdi
|
|
|
|
4 |
p. 447-470
|
artikel
|
| 5 |
Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment
|
Graff, Jochen
|
|
2013
|
|
4 |
p. 243-254
|
artikel
|
| 6 |
A Population Pharmacokinetic Analysis of PF-5190457, a Novel Ghrelin Receptor Inverse Agonist in Healthy Volunteers and in Heavy Alcohol Drinkers
|
Cobbina, Enoch
|
|
|
|
4 |
p. 471-484
|
artikel
|
| 7 |
A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation
|
Andrews, Louise M.
|
|
2017
|
|
4 |
p. 475-489
|
artikel
|
| 8 |
A Preterm Physiologically Based Pharmacokinetic Model. Part I: Physiological Parameters and Model Building
|
Abduljalil, Khaled
|
|
|
|
4 |
p. 485-500
|
artikel
|
| 9 |
A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use
|
Haahr, Hanne
|
|
2016
|
|
4 |
p. 339-354
|
artikel
|
| 10 |
A Review of Pharmacokinetic Drug–Drug Interactions with the Anthelmintic Medications Albendazole and Mebendazole
|
Pawluk, Shane Ashley
|
|
2015
|
|
4 |
p. 371-383
|
artikel
|
| 11 |
A Review of Pharmacokinetic Drug–Drug Interactions with the Anthelmintic Medications Albendazole and Mebendazole
|
Pawluk, Shane Ashley
|
|
|
|
4 |
p. 371-383
|
artikel
|
| 12 |
A Scoping Review of the Clinical Pharmacokinetics of Bedaquiline
|
Wilby, Kyle J.
|
|
|
|
4 |
p. 481-488
|
artikel
|
| 13 |
Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn’s Disease and Ulcerative Colitis
|
Ponce-Bobadilla, Ana Victoria
|
|
|
|
4 |
p. 623-634
|
artikel
|
| 14 |
A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug–Drug Interactions with Orally Administered Medications
|
Patel, Divya
|
|
|
|
4 |
p. 447-462
|
artikel
|
| 15 |
Author’s Reply to De Ponti et al.: “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus”
|
Scheen, André J.
|
|
2015
|
|
4 |
p. 449-451
|
artikel
|
| 16 |
Ciclosporin Population Pharmacokinetics and Bayesian Estimation in Thoracic Transplant Recipients
|
Fruit, Dorothée
|
|
2013
|
|
4 |
p. 277-288
|
artikel
|
| 17 |
Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir
|
Ramanathan, Srinivasan
|
|
2011
|
|
4 |
p. 229-244
|
artikel
|
| 18 |
Clinical Pharmacokinetics and Impact of Hematocrit on Monitoring and Dosing of Tacrolimus Early After Heart and Lung Transplantation
|
Sikma, Maaike A.
|
|
|
|
4 |
p. 403-408
|
artikel
|
| 19 |
Clinical Pharmacokinetics and Pharmacodynamics of CSL112
|
Ortega-Paz, Luis
|
|
|
|
4 |
p. 541-558
|
artikel
|
| 20 |
Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib
|
Puszkiel, Alicja
|
|
2018
|
|
4 |
p. 451-467
|
artikel
|
| 21 |
Clinical Pharmacokinetics and Pharmacodynamics of Desloratadine, Fexofenadine and Levocetirizine
|
Devillier, Philippe
|
|
2008
|
|
4 |
p. 217-230
|
artikel
|
| 22 |
Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer
|
Ketzer, Sander
|
|
2017
|
|
4 |
p. 455-473
|
artikel
|
| 23 |
Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer
|
Hirota, Takeshi
|
|
2018
|
|
4 |
p. 403-420
|
artikel
|
| 24 |
Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment
|
Zurth, Christian
|
|
|
|
4 |
p. 565-575
|
artikel
|
| 25 |
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
|
Gupta, Neeraj
|
|
2018
|
|
4 |
p. 431-449
|
artikel
|
| 26 |
Comment on: “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus”
|
Raschi, Emanuel
|
|
2015
|
|
4 |
p. 447-448
|
artikel
|
| 27 |
Comparing Dosage Adjustment Methods for Once-Daily Tobramycin in Paediatric and Adolescent Patients with Cystic Fibrosis
|
Hennig, Stefanie
|
|
2014
|
|
4 |
p. 409-421
|
artikel
|
| 28 |
Comprehensive Measurements of Intrauterine and Postnatal Exposure to Lamotrigine
|
Paulzen, Michael
|
|
2018
|
|
4 |
p. 535-543
|
artikel
|
| 29 |
Correction to: Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment
|
Agersnap, Mikkel Askjær
|
|
|
|
4 |
p. 653-654
|
artikel
|
| 30 |
Correction to: Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
|
Wojciechowski, Jessica
|
|
|
|
4 |
p. 591
|
artikel
|
| 31 |
Correction to: Unbound Plasma, Total Plasma and Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation
|
Sikma, Maaike A.
|
|
|
|
4 |
p. 589
|
artikel
|
| 32 |
Dosing in Children: A Critical Review of the Pharmacokinetic Allometric Scaling and Modelling Approaches in Paediatric Drug Development and Clinical Settings
|
Mahmood, Iftekhar
|
|
2014
|
|
4 |
p. 327-346
|
artikel
|
| 33 |
Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus
|
Scheen, André J.
|
|
2014
|
|
4 |
p. 295-304
|
artikel
|
| 34 |
Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dalcetrapib
|
Phelan, Mary
|
|
2013
|
|
4 |
p. 255-265
|
artikel
|
| 35 |
Effect of Molecular Weight and Substitution on Tissue Uptake of Hydroxyethyl Starch
|
Bellmann, Romuald
|
|
2012
|
|
4 |
p. 225-236
|
artikel
|
| 36 |
Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects
|
van Hout, Marloes
|
|
|
|
4 |
p. 635-644
|
artikel
|
| 37 |
Erratum to: Application of Modeling and Simulation to a Long-Term Clinical Trial: A Direct Comparison of Simulated Data and Data Actually Observed in Japanese Osteoporosis Patients Following 3-Year Ibandronate Treatment
|
Nakai, Kiyohiko
|
|
2015
|
|
4 |
p. 455
|
artikel
|
| 38 |
Erratum to Clinical Pharmacokinetics of Vinorelbine
|
Levêque, D.
|
|
1997
|
|
4 |
p. 323
|
artikel
|
| 39 |
Erratum to: Impact of New Genomic Technologies on Understanding Adverse Drug Reactions
|
Maggo, Simran D. S.
|
|
2016
|
|
4 |
p. 437
|
artikel
|
| 40 |
Erratum to: Individual bioequivalence: new concepts in the statistical assessment of bioequivalence metrics
|
Patnaik, R. N.
|
|
1997
|
|
4 |
p. 312
|
artikel
|
| 41 |
Erratum to: Kinetically Guided Neoadjuvant Chemoradiotherapy Based on 5-Fluorouracil in Patients with Locally Advanced Rectal Cancer
|
Grim, Jiří
|
|
2015
|
|
4 |
p. 453
|
artikel
|
| 42 |
Evaluating Plasma Pharmacokinetics of Intravenous Iron Formulations: Judging Books by Their Covers?
|
Pai, Amy Barton
|
|
2014
|
|
4 |
p. 323-324
|
artikel
|
| 43 |
Evaluating the Relationship Between Lean Liver Volume and Fat-Free Mass
|
Sinha, Jaydeep
|
|
|
|
4 |
p. 475-483
|
artikel
|
| 44 |
Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Lineshape Analysis
|
Peters, Sheila Annie
|
|
2008
|
|
4 |
p. 261-275
|
artikel
|
| 45 |
Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole
|
Yang, Eunsol
|
|
|
|
4 |
p. 599-608
|
artikel
|
| 46 |
Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease
|
van der Aart-van der Beek, Annemarie B.
|
|
|
|
4 |
p. 517-525
|
artikel
|
| 47 |
Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist
|
Younis, Islam
|
|
|
|
4 |
p. 609-621
|
artikel
|
| 48 |
Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis
|
Li, Rui
|
|
2017
|
|
4 |
p. 491-503
|
artikel
|
| 49 |
External Evaluation of Population Pharmacokinetic Models for Precision Dosing: Current State and Knowledge Gaps
|
El Hassani, Mehdi
|
|
|
|
4 |
p. 533-540
|
artikel
|
| 50 |
Facilitation of Drug Evaluation in Children by Population Methods and Modelling
|
Tod, Michel
|
|
2008
|
|
4 |
p. 231-243
|
artikel
|
| 51 |
Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus
|
Davis, Abigayle
|
|
2018
|
|
4 |
p. 421-430
|
artikel
|
| 52 |
Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs
|
Calcagno, Andrea
|
|
2016
|
|
4 |
p. 355-369
|
artikel
|
| 53 |
Genotypes Affecting the Pharmacokinetics of Anticancer Drugs
|
Bertholee, Daphne
|
|
2016
|
|
4 |
p. 317-337
|
artikel
|
| 54 |
Identification of Intestinal Loss of a Drug through Physiologically Based Pharmacokinetic Simulation of Plasma Concentration-Time Profiles
|
Peters, Sheila Annie
|
|
2008
|
|
4 |
p. 245-259
|
artikel
|
| 55 |
Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P1 Receptor Modulator Ponesimod Based on 13 Clinical Studies
|
Lott, Dominik
|
|
2016
|
|
4 |
p. 395-408
|
artikel
|
| 56 |
Impact of New Genomic Technologies on Understanding Adverse Drug Reactions
|
Maggo, Simran D. S.
|
|
2015
|
|
4 |
p. 419-436
|
artikel
|
| 57 |
Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma
|
Yan, Xiaoyu
|
|
2017
|
|
4 |
p. 529-538
|
artikel
|
| 58 |
Influence of Gestational Age and Body Weight on the Pharmacokinetics of Labetalol in Pregnancy
|
Fischer, James H.
|
|
2013
|
|
4 |
p. 373-383
|
artikel
|
| 59 |
Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
|
Boulton, David
|
|
2011
|
|
4 |
p. 253-265
|
artikel
|
| 60 |
Influence of Sex and Race on Mycophenolic Acid Pharmacokinetics in Stable African American and Caucasian Renal Transplant Recipients
|
Tornatore, Kathleen M.
|
|
2014
|
|
4 |
p. 423-434
|
artikel
|
| 61 |
Integrated Population Pharmacokinetic/Viral Dynamic Modelling of Lopinavir/Ritonavir in HIV-1 Treatment-Naïve Patients
|
Wang, Kun
|
|
2013
|
|
4 |
p. 361-371
|
artikel
|
| 62 |
Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1
|
Berger, Juliette
|
|
2018
|
|
4 |
p. 469-482
|
artikel
|
| 63 |
Key Pharmacokinetic Essentials of Fixed-Dosed Combination Products: Case Studies and Perspectives
|
Dash, Ranjeet Prasad
|
|
2017
|
|
4 |
p. 419-426
|
artikel
|
| 64 |
Modelling and Simulation of the Positive and Negative Syndrome Scale (PANSS) Time Course and Dropout Hazard in Placebo Arms of Schizophrenia Clinical Trials
|
Reddy, Venkatesh Pilla
|
|
2012
|
|
4 |
p. 261-275
|
artikel
|
| 65 |
Nicotine Population Pharmacokinetics in Healthy Smokers After Intravenous, Oral, Buccal and Transdermal Administration
|
Olsson Gisleskog, Per O.
|
|
|
|
4 |
p. 541-561
|
artikel
|
| 66 |
Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited
|
Bensalem, Amina
|
|
|
|
4 |
p. 519-530
|
artikel
|
| 67 |
Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics
|
Rodvold, Keith A.
|
|
|
|
4 |
p. 409-425
|
artikel
|
| 68 |
Oral Bioavailability: Issues and Solutions via Nanoformulations
|
Pathak, Kamla
|
|
2015
|
|
4 |
p. 325-357
|
artikel
|
| 69 |
Oral Delivery of Antibodies
|
Reilly, Raymond M.
|
|
|
|
4 |
p. 313-323
|
artikel
|
| 70 |
PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
|
Geenen, Jill J. J.
|
|
2017
|
|
4 |
p. 427-437
|
artikel
|
| 71 |
Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer’s Disease
|
Noetzli, Muriel
|
|
2013
|
|
4 |
p. 225-241
|
artikel
|
| 72 |
Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions
|
Magréault, Sophie
|
|
|
|
4 |
p. 409-445
|
artikel
|
| 73 |
Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation
|
Angiolillo, Dominick J.
|
|
|
|
4 |
p. 465-479
|
artikel
|
| 74 |
Pharmacokinetic Interaction of Vicriviroc with Other Antiretroviral Agents
|
Kasserra, Claudia
|
|
2011
|
|
4 |
p. 267-280
|
artikel
|
| 75 |
Pharmacokinetics and Pharmacodynamics of Intraperitoneal Cancer Chemotherapeutics
|
Hasovits, Csilla
|
|
2012
|
|
4 |
p. 203-224
|
artikel
|
| 76 |
Pharmacokinetics and Pharmacodynamics of Mepolizumab, an Anti-Interleukin-5 Monoclonal Antibody
|
Smith, Deborah A.
|
|
2011
|
|
4 |
p. 215-227
|
artikel
|
| 77 |
Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review
|
Appeldoorn, T. Y. J.
|
|
|
|
4 |
p. 559-571
|
artikel
|
| 78 |
Pharmacokinetics and Pharmacodynamics of Tedizolid
|
Iqbal, Khalid
|
|
|
|
4 |
p. 489-503
|
artikel
|
| 79 |
Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015 % and Timolol 0.5 % in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies
|
Kaarniranta, Kai
|
|
2015
|
|
4 |
p. 485-494
|
artikel
|
| 80 |
Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases
|
Balevic, Stephen J.
|
|
2018
|
|
4 |
p. 525-533
|
artikel
|
| 81 |
Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment
|
Chevalier, Clémence
|
|
|
|
4 |
p. 485-490
|
artikel
|
| 82 |
Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy
|
Wenzler, Eric
|
|
|
|
4 |
p. 539-552
|
artikel
|
| 83 |
Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment
|
Agersnap, Mikkel Askjær
|
|
|
|
4 |
p. 645-651
|
artikel
|
| 84 |
Pharmacokinetic Study of Mycophenolate Mofetil in Patients with Systemic Lupus Erythematosus and Design of Bayesian Estimator Using Limited Sampling Strategies
|
Zahr, Noël
|
|
2008
|
|
4 |
p. 277-284
|
artikel
|
| 85 |
Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes
|
Marzolini, Catia
|
|
2016
|
|
4 |
p. 409-420
|
artikel
|
| 86 |
Physiologically Based Pharmacokinetic Prediction of Linezolid and Emtricitabine in Neonates and Infants
|
Duan, Peng
|
|
2016
|
|
4 |
p. 383-394
|
artikel
|
| 87 |
Placental Transfer of Antidepressant Medications: Implications for Postnatal Adaptation Syndrome
|
Ewing, Grace
|
|
2015
|
|
4 |
p. 359-370
|
artikel
|
| 88 |
Pooled Population Pharmacokinetic Analysis of Phase I, II and III Studies of Linifanib in Cancer Patients
|
Salem, Ahmed Hamed
|
|
2013
|
|
4 |
p. 347-359
|
artikel
|
| 89 |
Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours
|
Gibiansky, Leonid
|
|
2012
|
|
4 |
p. 247-260
|
artikel
|
| 90 |
Population Pharmacokinetic Analysis of Lanreotide Autogel®/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials
|
Buil-Bruna, Núria
|
|
2015
|
|
4 |
p. 461-473
|
artikel
|
| 91 |
Population Pharmacokinetic Analysis to Assist Dose Selection of the l-Ornithine Salt of Phenylacetic Acid
|
Wang, Xiaofeng
|
|
|
|
4 |
p. 515-526
|
artikel
|
| 92 |
Population Pharmacokinetic Meta-Analysis to Bridge Ferumoxytol Plasma Pharmacokinetics Across Populations
|
Plock, Nele
|
|
2014
|
|
4 |
p. 385-395
|
artikel
|
| 93 |
Population Pharmacokinetic Modeling of Thymoglobulin® in Children Receiving Allogeneic-Hematopoietic Cell Transplantation: Towards Improved Survival Through Individualized Dosing
|
Admiraal, Rick
|
|
2014
|
|
4 |
p. 435-446
|
artikel
|
| 94 |
Population Pharmacokinetic-Pharmacodynamic Modelling of 24-h Diastolic Ambulatory Blood Pressure Changes Mediated by Axitinib in Patients with Metastatic Renal Cell Carcinoma
|
Chen, Ying
|
|
2014
|
|
4 |
p. 397-407
|
artikel
|
| 95 |
Population Pharmacokinetics and Dosing Simulations of Ampicillin and Sulbactam in Hospitalised Adult Patients
|
Setiawan, Eko
|
|
|
|
4 |
p. 573-586
|
artikel
|
| 96 |
Population Pharmacokinetics and Exposure–Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer
|
Ly, Neang S.
|
|
|
|
4 |
p. 587-598
|
artikel
|
| 97 |
Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials
|
Jones, Aksana K.
|
|
|
|
4 |
p. 527-540
|
artikel
|
| 98 |
Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia
|
Magnusson, Mats O.
|
|
2016
|
|
4 |
p. 421-433
|
artikel
|
| 99 |
Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies
|
Clements, John David
|
|
|
|
4 |
p. 463-474
|
artikel
|
| 100 |
Population Pharmacokinetics of Continuous Infusion Ceftazidime
|
Frame, Bill C.
|
|
|
|
4 |
p. 343-350
|
artikel
|
| 101 |
Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids
|
Beck, Denise
|
|
|
|
4 |
p. 577-587
|
artikel
|
| 102 |
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression
|
Perez-Ruixo, Carlos
|
|
|
|
4 |
p. 501-516
|
artikel
|
| 103 |
Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens
|
Shah, Gunjan L.
|
|
|
|
4 |
p. 553-563
|
artikel
|
| 104 |
Population Pharmacokinetics of Tobramycin in Patients With and Without Cystic Fibrosis
|
Hennig, Stefanie
|
|
2013
|
|
4 |
p. 289-301
|
artikel
|
| 105 |
Population Pharmacokinetics of Tranexamic Acid in Paediatric Patients Undergoing Craniosynostosis Surgery
|
Goobie, Susan M.
|
|
2013
|
|
4 |
p. 267-276
|
artikel
|
| 106 |
Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets
|
Yu, Huixin
|
|
2014
|
|
4 |
p. 305-325
|
artikel
|
| 107 |
Predicting Cortisol Exposure from Paediatric Hydrocortisone Formulation Using a Semi-Mechanistic Pharmacokinetic Model Established in Healthy Adults
|
Melin, Johanna
|
|
2017
|
|
4 |
p. 515-527
|
artikel
|
| 108 |
Predicting Drug Candidate Victims of Drug-Drug Interactions, using Microdosing
|
Croft, Marie
|
|
2012
|
|
4 |
p. 237-246
|
artikel
|
| 109 |
Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA
|
Wagner, Christian
|
|
2015
|
|
4 |
p. 475-483
|
artikel
|
| 110 |
Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs
|
Borella, Elisa
|
|
2017
|
|
4 |
p. 505-514
|
artikel
|
| 111 |
Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population
|
Abduljalil, Khaled
|
|
|
|
4 |
p. 501-518
|
artikel
|
| 112 |
Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Study of QGC001, a Centrally Acting Aminopeptidase A Inhibitor Prodrug
|
Balavoine, Fabrice
|
|
2013
|
|
4 |
p. 385-395
|
artikel
|
| 113 |
Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency
|
Cojutti, Pier Giorgio
|
|
|
|
4 |
p. 505-513
|
artikel
|
| 114 |
Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [11C]DASB PK-PD Study
|
Kim, Euitae
|
|
2016
|
|
4 |
p. 371-381
|
artikel
|
| 115 |
Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes
|
Stader, Felix
|
|
2018
|
|
4 |
p. 483-501
|
artikel
|
| 116 |
Ritonavir
|
Hsu, Ann
|
|
1998
|
|
4 |
p. 275-291
|
artikel
|
| 117 |
Should the Clinical Pharmacologist Play a Role in the Multidisciplinary Team Managing Severe Necrotizing Soft-Tissue Infections?
|
Gatti, Milo
|
|
|
|
4 |
p. 403-407
|
artikel
|
| 118 |
The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers
|
Morrissey, Kari M.
|
|
2015
|
|
4 |
p. 495-506
|
artikel
|
| 119 |
The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations
|
Echizen, Hirotoshi
|
|
2015
|
|
4 |
p. 409-418
|
artikel
|
| 120 |
The Influence of Haemostatic System Maturation on the Dose–Response Relationship of Unfractionated Heparin
|
Derbalah, Abdallah
|
|
|
|
4 |
p. 491-499
|
artikel
|
| 121 |
The Pharmacokinetics of Methanol in the Presence of Ethanol
|
Coulter, Carolyn
|
|
2011
|
|
4 |
p. 245-251
|
artikel
|
| 122 |
Therapeutic Concentrations of Metformin: A Systematic Review
|
Kajbaf, Farshad
|
|
2015
|
|
4 |
p. 439-459
|
artikel
|
| 123 |
Therapeutic Drug Monitoring of Antiepileptic Drugs in Women with Epilepsy Before, During, and After Pregnancy
|
Arfman, Inge J.
|
|
|
|
4 |
p. 427-445
|
artikel
|
| 124 |
Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer
|
Braal, C. Louwrens
|
|
|
|
4 |
p. 527-537
|
artikel
|
Tijdschrift beschrijving